Tapering is arithmetic. Treating the pain is the work.

Most patients arriving for a taper have heard the word used as a threat. Something done to them, on somebody else's timetable, because of somebody else's guideline.

That is not what a taper is for.

"Tapering is not a treatment," says Dr. Gurpreet Singh Padda, MD, MBA, MHP. "It is arithmetic. If you have not changed why the patient needed the medication, you have not treated anything. You have moved a number."

At the Padda Institute Center for Interventional Pain Management, the taper measures what the body can now do for itself. If the terrain has improved, the taper reveals it. If it has not, the taper says so, and the plan changes. This page is part of the practice's opioid stewardship work.

Who is this for?

People already on long-term opioids whose treatment has stopped working:

• The dose keeps climbing. The pain keeps climbing with it.
• A primary care physician handed you off at a high dose. The practice frequently inherits patients at 400 to 500 MME.
• You were told to taper, or tapered fast, with nothing put in the medication's place.
• You take an opioid and a benzodiazepine, usually from two different prescribers.

It is not for anyone looking to start, keep or raise a dose indefinitely. The practice does not accept patients seeking opioids as the treatment and does not offer medication-only management. You do not have to come off opioids to be seen. You do have to treat what is causing the pain.

Dr. Padda does not soften that conversation: "I usually start off my conversation with you're probably going to call me an asshole but this is what we need to do… you're not going to like me in the process but you're going to like me at the end." Patients managed politely for years, while getting worse, deserve the straight version.

Why do opioids stop working?

Because the account runs dry from both ends. Dr. Padda calls it opioid bankruptcy: income collapses while expenses rise.

Expenses rise. The mu-opioid receptor is built to cycle: bind, signal, desensitize, recover. Continuous occupancy blocks the recovery. The same dose does less. The dose climbs. The receptor is occupied even more continuously. Past a point the drug feeds the pain it was prescribed to treat. That is opioid-induced hyperalgesia, routinely misread as disease progression or drug-seeking and answered with more drug.

Income collapses. You manufacture your own pain relief: endorphins and enkephalins. Chronic external opioids suppress that machinery and the hypothalamic-pituitary-gonadal axis with it. Low testosterone, fatigue, flat mood and poor recovery follow. Broken sleep drains the rest. One bad night measurably lowers the next day's pain threshold.

Reward flattens. The same mu-opioid system that blocks pain amplifies pleasure. Flatten it, and refined, palatable food becomes the fastest lever left. That is hedonic substitution. The weight comes on, metabolic inflammation rises, and the pain rises with it. These patients do not lack discipline. Their reward system has been flattened.

Context decides the rest. Roughly 20% of American soldiers in Vietnam became addicted to opioids in theater. In the first year home, about 5% relapsed. Most received no treatment. The molecule did not change. The cues, the stress, the peer group and the purpose did. That is why the first visit asks about sleep, food, work and who is at home.

Long-acting formulations are the worst offenders. They are engineered to erase the trough between doses. The trough is when the receptor recovers.

Why is an abrupt taper harmful?

Stopping a long-term opioid does not subtract a drug. It rips a suppressant out of a nervous system that has rebuilt itself around it. The result is predictable:

• Withdrawal. Physiologically miserable. In medically fragile patients, genuinely dangerous.
• Rebound pain, worse than before, because the adapted system is now unopposed.
• Lost function, exactly when the patient needs to take part in rehabilitation.
• Lost relationship, the thing most likely to keep that patient safe next year.

Some go looking for a prescriber. Some stop looking for care at all. Neither shows up in the metric that made the taper look successful. Older adults and cancer patients take the worst of it.

The CDC's 2022 guideline says opioid therapy should not be discontinued abruptly, or reduced rapidly from higher doses, unless there is a life-threatening issue. Large observational studies associate faster tapers with more overdose and more mental health crisis.

"First, do no harm" was never a mandate to do nothing. A physician who prescribes without a plan has failed. So has one who tapers without one.

How does evaluation work?

Medical necessity rests on three independent data streams:

• Symptom mapping. Documented chronic pain, typically at least one to three months, that failed physical therapy, chiropractic care and non-narcotic medication trials.
• Multimodal correlation. MRI, CT or X-ray plus EMG and nerve conduction testing, matching the pain report to a structural or neurological finding. Digital whole body X-ray is done on site.
• Metabolic and inflammatory assessment. Chronic pain is frequently an extension of systemic metabolic inflammation.

Risk is stratified with validated instruments, applied to everyone:

• Substance use: Opioid Risk Tool, DAST, NIDA single-question screen, ASSIST, and AUDIT for alcohol.
• Psychiatric: PHQ-9, GAD-7, Mood Disorder Questionnaire, Altman Mania Scale.
• Developmental: Adverse Childhood Experiences scoring.
• Cognitive: neuropsychological screening of decision-making capacity. A Cognivue baseline before a taper shows the cognitive cost of the higher dose instead of asserting it.

Prescription monitoring program records are reviewed. Missouri law limits the practice to the Missouri program for patients seen in Missouri, so patients who also receive care in a neighboring state supply a release for those records.

What takes over the medication's work?

A dose can come down safely only when something else carries the load. That is the entire clinical purpose of interventional pain management.

Every injection and nerve procedure runs under fluoroscopic or ultrasound guidance. Diagnostic blocks prove which structure produces the pain before anything is treated. Then the generator is treated: epidural and nerve root injections, facet and genicular radiofrequency ablation, basivertebral nerve ablation, stimulation, celiac plexus block, and ketamine where central sensitization has set in.

One number shows the principle. In the randomized trial behind basivertebral nerve ablation, 36 percent of patients took opioids at enrollment. Twenty-four months after ablation, 62 percent fewer did.

The full toolkit, matched condition by condition, is on the non-opioid pain treatment page.

How fast does the dose come down?

As fast as the patient's physiology allows. No faster.

Medication is a bridge, and not a bridge you can live on. Bridges carry you across something. They are not built to be stood on forever, and the structure is not designed for that load. None of that argues for pulling the bridge out mid-crossing.

The pace is calculated from three inputs: clinical stability, progress in physical therapy and movement, and metabolic markers. Never an arbitrary schedule.

• Inherited high doses generally reach a routine dose within one to three months.
• In-person review every two weeks for everyone on long-term controlled substances. Adjustments happen in days, not quarters.
• The timeline moves. Cognitive and psychometric screening runs throughout. If physiology says slow down, the taper slows down.
• Clonidine facilitates opioid reduction in patients arriving on high doses.
• Formal medication review every four months. No functional improvement means medication is tapered and care may return to the primary physician.
• Repeat procedures earn their place. A repeat intervention requires documented functional improvement of at least 50%.

What if I also take a benzodiazepine?

One of them comes off.

An opioid blunts the brainstem's response to rising carbon dioxide. A benzodiazepine potentiates GABA-A, the brain's main inhibitory signal. Two mechanisms, one consequence: less drive to breathe. Together the effect is synergistic, not additive. The FDA carries a boxed warning on the combination. Alcohol hits the same system.

Coming off the benzodiazepine is the harder job. Opioid withdrawal is miserable and rarely dangerous. Benzodiazepine withdrawal can cause seizures. The wean is slow and front-loaded. Six months or more is normal. The last portion is the hardest, and rushing it is how tapers fail. Severe PTSD and some psychiatric presentations may stop short of zero. Severe spasticity is a legitimate reason to stay on one.

Zolpidem and eszopiclone act at the same receptor site. Carisoprodol metabolizes to meprobamate, which acts similarly. Bring the actual bottles.

What will the practice ask of me?

Participation is mandatory, not advisory.

• Physical therapy: at least 12 sessions a year.
• Counseling: ongoing psychological counseling for opioid harm reduction with the in-house clinical psychologist. Most tapers fail without it.
• Metabolic work: metabolic health testing and nutritional and lifestyle coaching.

Failure to participate is grounds for discharge, because the care no longer meets the criteria for medical necessity.

The medication agreement, signed before treatment:

• No sharing, selling or trading medication. No illicit substances.
• One designated pharmacy, with advance notice of any change.
• No controlled substances from another provider without telling the practice first.
• Lost or stolen medication is not routinely replaced. No early fills.

Monitoring:

• Every bottle comes to every visit for a physical count.
• Urine drug testing every six to twelve weeks at an independent high-complexity laboratory, using gas chromatography. A missing prescribed drug is flagged as seriously as an illicit one.
• Electronic prescribing only. No verbal or telephoned prescriptions.
• The practice never dispenses more than a patient could foreseeably overdose on at one time.
• Overdose awareness education and naloxone training for every patient prescribed an opioid.
• No telehealth for this population. All patients on long-term controlled substances are seen in person.

Violations end the treatment relationship without refills.

Is the goal always zero?

No. The preference is to avoid opioids altogether. In complex cases that is not always achievable.

The practice reports its results by tier. These are practice-reported figures from our own population, not trial outcomes, and individual results vary.

• Arriving: the average new patient has been in pain more than two and a half years and takes more than 90 MME per day.
• Under active interventional treatment: 21% are completely weaned off opioid pain medication within 90 days, and 34% are completely weaned off all opioid pain medication within one year. Of those who cannot be fully weaned, the large majority are brought below 30 MME per day.
• Established: approximately 60 to 65% receive any opioid analgesic at all. The average maintained patient sits at approximately 27 to 32.5 MME, with typical dosing under 30 to 40 MME. Fewer than 1% remain above 90 MME, limited to active cancer pain under co-management or postoperative failed back surgery syndrome and arachnoiditis, where the higher dose is temporizing during reduction.

"Arrives above 90" and "fewer than 1% stay above 90" are the starting line and the result, not a contradiction.

If opioid use disorder is part of the picture, the Addictionology Center provides in-person buprenorphine/naloxone treatment. For an older parent in a facility, see the DWARAA deprescribing framework.

How do I start?

The Padda Institute is at 4477 Woodson Rd, Suite 100, St. Louis, MO 63134, next to the airport. Call (314) 481-5000 or text (314) 886-5902 to schedule. Medication questions are handled at your visit or by phone, never by text.

Do not stop or change a prescribed medication before you are seen. Not sure this program fits? Tap the directory assistant, the light in the corner of this page, and it will point you to the right place.

Frequently asked questions

What should I bring to the first visit?

Every medication bottle, your imaging and your prior records, including any from out-of-state prescribers.

Why is my pain worse after a previous doctor stopped my opioids?

Rebound pain. Your nervous system adapted to the drug. Remove it abruptly and the adapted system runs unopposed. That experience does not mean a taper cannot work. It means that one had nothing on the other side.

Why won't you switch me to a long-acting opioid to reduce my pill count?

Fewer tablets is not less risk. A long-acting formulation keeps the receptor occupied around the clock, and observational data associate long-acting agents with higher overdose risk and total mortality.

Can I be tapered off a benzodiazepine and an opioid at the same time?

The plan is individual, but the benzodiazepine taper is the slower and more dangerous of the two. It is never done abruptly or without supervision.

Do you continue a prescription while I decide about procedures?

Not as a plan on its own. Patients must be willing to undergo procedural treatment. The practice takes over care to reduce the dose while procedures treat the generator.